Navigation Links
Novel export-inhibitor shows promise for treating CLL
Date:12/12/2011

An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The agent, called KPT-SINE, belongs to a new class of drugs called selective inhibitors of nuclear export (SINE). The agent was developed by Karyopharm Therapeutics Inc. It is designed to kill cancer cells by restoring biochemical pathways that normally cause unhealthy cells to self-destruct through a process called programmed cell death, or apoptosis.

The agent targets a protein called CRM1, which, until now, has not been adequately explored in CLL, the researchers say. During disease progression, cancer cells use CRM1 to shunt certain apoptosis-related proteins out of the nucleus, thereby avoiding cell death.

"We believe that KPT-SINE and other nuclear-export inhibitors may represent a unique, entirely new therapeutic strategy for treating cancer by simultaneously restoring multiple normal cell death pathways," says OSUCCC James research scientist Dr. Rosa Lapalombella who is a co-investigator on the study with Dr. John Byrd, director of the division of hematology and co-director of the OSUCCC James CLL Experimental Therapeutics Laboratory at OSUCCC James.

The researchers hypothesize that KPT-SINE will inhibit CRM1 and keep these regulatory proteins in the nucleus where they can initiate programmed cell death.

Lapalombella will discuss the role of CRM1 inhibition in the treatment of CLL on Monday, December 12, at 7:00 a.m. during the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

The study, which used CLL cells from patients and a mouse model of CLL, provides essential proof-of-concept data to design and initiate phase I clinical testing of KPT-SINE in patients with these incurable diseases, Lapalombella notes.

"We are excited by our preliminary findings that KPT-SINE represents a promising targeted therapy for CLL patients," Byrd says. "We look forward to transitioning our research toward early clinical development in patients with CLL and related diseases, based upon the data generated by our team."
'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Novel experimental agent is highly active in CLL patients, interim study shows
2. Researchers identify a novel therapeutic approach for liver cancer
3. Novel drug wipes out deadliest malaria parasite through starvation
4. Novel approach to treating breast cancer shows great promise
5. Wayne State receives $1.9 million from NIH to create novel cystic fibrosis treatments
6. Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial
7. Wayne State University to study novel treatment for antibiotic-resistant bacteria
8. Novel, noninvasive measurement a strong predictor for heart failure in general population
9. UK HealthCare surgeons are first to perform novel procedures prior to transplant
10. Novel approach to treat proliferative vitreoretinopathy shows promise
11. Novel strategy stymies SARS et al.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic Trainers from ... Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, evidence based ... Trainers are acknowledged by their peers with accolades and highly prestigious awards. This ...
(Date:9/20/2017)... ... 2017 , ... The Centers for Medicare and Medicaid Services (CMS) stated in ... using only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated Care Payments over ... webinars on October 17, 2017 at 2 P.M. EST and uncover how you ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face ... tribulations as he emotionally pens his aspirations and goals to better one’s life through ... author, Jimmy Green, while searching in all the wrong places, found a love for ...
(Date:9/20/2017)... ... September 20, 2017 , ... Ron Norman, CEO of ... this week about the value of senior executives, pointed to a quote from ... business has brought us to the present and will lead us into the ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “They Sang At ... hunt for a murderer starts revealing the skeletons in their closets. “They Sang At ... who is now fifty-six years young and married with five children and twelve grandchildren. ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
Breaking Medicine Technology: